We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Adamis

News List

Adamis Appoints David C. Benedicto as CFO firstwordpharma
August 25, 2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that David C. Benedicto, who has been serving as the Company's Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately.
Adamis Announces Agreement to Sell Portion of US Compounding Business firstwordpharma
August 05, 2021
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a definitive agreement to sell a significant portion of the assets of its subsidiary, US Compounding Inc. (USC), related to USC's human compounding pharmaceutical
Adamis Provides Update on Zimhi drugs
June 21, 2021
Adamis Pharmaceuticals Corporation today announced that the FDA has accepted for review the Company’s resubmitted New Drug Application (NDA) for ZIMHI™, which is its higher naloxone injection product candidate for the treatment of opioid overdose.
Adamis submits IND application to FDA for Covid-19 treatment pharmaceutical-technology
January 22, 2021
Speciality biopharmaceutical company Adamis Pharmaceuticals has submitted an Investigational New Drug (IND) to the US Food and Drug Administration (FDA) for the use of Tempol to treat Covid-19.